Lee Hyun-A, Jeong Hyunjoo, Kim Eun-Young, Nam Mi Young, Yoo Yun-Jung, Seo Jeong-Taeg, Shin Dong Min, Ohk Seung-Ho, Lee Syng-Ill
Department of Oral Biology, Yonsei University College of Dentistry, Seoul 120-749, Korea.
Exp Physiol. 2003 Sep;88(5):569-74. doi: 10.1113/eph8802558.
The Na(+)-K(+)-2Cl(-) cotransporter (NKCC1) is responsible for ion transport across the secretory and absorptive epithelia, the regulation of cell volume, and possibly the modulation of cell growth and development. It has been reported that a variety of cells, including osteoblasts, contain this cotransporter. In this study, the physiological role of NKCC1 in osteoclastogenesis was exploited in a co-culture system. Bumetanide, a specific inhibitor of NKCC1, reduced the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells. In order to investigate the mechanism by which bumetanide inhibits osteoclastogenesis, the mRNA expressions of the receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) and osteoprotegerin (OPG) were analysed by RT-PCR. Exposure of osteoblastic cells to a medium containing 1 micro M bumetanide reduced RANKL mRNA expression induced by 10 nM 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3, in a dose-dependent manner. In addition, RANKL expression was also analysed with enzyme-linked immunosorbant assay (ELISA) using anti-RANKL antibody. The expression of RANKL was decreased with the increase of bumetanide concentration. In contrast, the expression of OPG mRNA, a novel tumour necrosis factor (TNF) receptor family member was increased in the presence of bumetanide. These results imply that bumetanide inhibits osteoclast differentiation by reducing the RANKL/OPG ratio in osteoblastic cells. However, no significant difference in M-CSF mRNA expression was observed when bumetanide was added. Also, we found that the phosphorylation of c-Jun NH2-terminal kinase (JNK), which regulates the activity of various transcriptional factors, was reduced by bumetanide treatment. Conclusively, these findings suggest that NKCC1 in osteoblasts has a pivotal role in 1alpha,25(OH)2D3-induced osteoclastogenesis partly via the phosphorylation of JNK.
钠-钾-2氯协同转运蛋白(NKCC1)负责跨分泌性和吸收性上皮的离子转运、细胞体积调节,还可能参与细胞生长和发育的调控。据报道,包括成骨细胞在内的多种细胞都含有这种协同转运蛋白。在本研究中,利用共培养系统探究了NKCC1在破骨细胞生成中的生理作用。布美他尼是NKCC1的特异性抑制剂,它可减少抗酒石酸酸性磷酸酶(TRAP)阳性多核细胞的数量。为了研究布美他尼抑制破骨细胞生成的机制,通过逆转录聚合酶链反应(RT-PCR)分析了核因子(NF)-κB受体激活剂配体(RANKL)和骨保护素(OPG)的mRNA表达。将成骨细胞暴露于含有1 μM布美他尼的培养基中,可呈剂量依赖性地降低由10 nM 1α,25-二羟基维生素D3(1α,25(OH)2D3)诱导的RANKL mRNA表达。此外,还使用抗RANKL抗体通过酶联免疫吸附测定(ELISA)分析了RANKL的表达。随着布美他尼浓度的增加,RANKL的表达降低。相反,在布美他尼存在的情况下,新型肿瘤坏死因子(TNF)受体家族成员OPG mRNA的表达增加。这些结果表明,布美他尼通过降低成骨细胞中的RANKL/OPG比值来抑制破骨细胞分化。然而,添加布美他尼时,M-CSF mRNA表达未观察到显著差异。此外,我们发现布美他尼处理可降低调节各种转录因子活性的c-Jun氨基末端激酶(JNK)的磷酸化水平。总之,这些发现表明,成骨细胞中的NKCC1在1α,25(OH)2D3诱导的破骨细胞生成中部分通过JNK的磷酸化发挥关键作用。